TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00023673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: three-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: three-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: three-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: three-dimensional conformal radiation therapy
Study: NCT03345485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 60mg/m2 over 60min
Description: Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 80mg/m2 over 60min
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 80mg/m2 over 60min
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 80mg/m2 over 60min
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 80mg/m2 over 60min
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 80mg/m2 over 60min
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study: NCT03843502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kava Dietary Supplement
Description: Participants will be given three 75mg kava capsules.
Study: NCT03845257

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling
Description: Blood sampling (eosinophil count; eosinophilia is defined as \>300/µl (or \>150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling
Description: Blood sampling (eosinophil count; eosinophilia is defined as \>300/µl (or \>150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.
Study: NCT03783351

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C19 genotype testing
Description: CYP2C19 genotype testing will be conducted in a designated central laboratory.
Study: NCT01040871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE
Description: VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
Study: NCT03600506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive infusion of study drug intravenously 10 minutes before induction of anesthesia as 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr till the start of wound closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fifty ml of Placebo (normal saline) will be prepared and given intravenously by a syringe pump over 10 minutes initially and then over 1 hour till the start of wound closure.
Study: NCT01943370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early saline irrigation
Description: Initiation of post-operative saline irrigation earlier during the post-operative course
Study: NCT01040871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
Study: NCT02200042

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Patients undergo 15 fractions of image-guided radiation therapy delivered over 19-26 or 27-34 days.
Study: NCT04175262

Intervention type: DRUG
Intervention: sunitinib
Description: Patients to receive sunitinib as second line therapy for mRCC
Study: NCT03684798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MCII
Description: In this study, the research staff will work through the MCII approach with the participant as an interactive, face-to-face training. The desired future consists of imaging an abstinent life and comparing it with personally relevant obstacles. Afterwards, the most relevant obstacle will be chosen and an if-then-plan will be formed, that refers to this obstacle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The patients in the control group will receive a 2 x 2 contingency table about the disadvantages and advantages of being abstinent and of drinking. In addition, abstinence intentions of patients in the control group will also be supported and risk situations and relapse events since the last trainings will be reappraised, but without the use of MCII.
Study: NCT03770572

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Low dose AT-GTX-502
Description: Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at low dose

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: High dose AT-GTX-502
Description: Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at high dose
Study: NCT01179594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: 0.5 mg orally daily, 24 weeks (weeks 12-36)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: 0.5 mg orally daily, 24 weeks (weeks 12-36)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 96 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally daily, 24 weeks (weeks 12-36)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally daily, 24 weeks (weeks 12-36)
Study: NCT02414087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICB Medical insoles
Description: Study group:~Participants in the study group will be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months.~Control group:~Participants in the control group will not be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months
Study: NCT02602574

Intervention type: OTHER
Intervention: heparinized peripheral venous blood and urine sample.
Description: All patients will be taken heparinized peripheral venous blood and urine sample

Intervention type: OTHER
Intervention: heparinized peripheral venous blood and urine sample.
Description: All patients will be taken heparinized peripheral venous blood and urine sample

Intervention type: OTHER
Intervention: heparinized peripheral venous blood and urine sample.
Description: All patients will be taken heparinized peripheral venous blood and urine sample
Study: NCT01842009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Definition transcranial Direct Current Stimulation
Study: NCT03345485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 80mg/m2 over 60min
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 100mg/m2 over 60min
Description: Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 80mg/m2 over 80min
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 80 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study: NCT03910101

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand surgery and intensive rehabilitation
Description: Spasticity-correcting upper-limb surgery comprised lengthening of tendons, release of muscles, and occasionally correction of deformities. Rehabilitation starts the first post-operative day and comprised physiotherapy and occupational therapy. Patients are also taught a home-training program. Up to 1 week of intensive in-hospital rehabilitation followed 3 weeks after surgery and a new home-training program are designed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand surgery and intensive rehabilitation
Description: Spasticity-correcting upper-limb surgery comprised lengthening of tendons, release of muscles, and occasionally correction of deformities. Rehabilitation starts the first post-operative day and comprised physiotherapy and occupational therapy. Patients are also taught a home-training program. Up to 1 week of intensive in-hospital rehabilitation followed 3 weeks after surgery and a new home-training program are designed.
Study: NCT01922596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03084328

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamind D
Description: Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months
Study: NCT04526808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FODMAP diet
Description: low FODMAP diet
Study: NCT02762409

Intervention type: OTHER
Intervention: experimental
Description: corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015

Intervention type: OTHER
Intervention: control
Description: The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015
Study: NCT02527720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Therapy
Description: BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention. A key component in BBMT is to be mindful of breathing whenever possible, and breathe at near resonance frequency (RF), known as heart rate variability biofeedback. The human cardiovascular system is known to have resonance characteristics, with the first RF at \~0.1 Hz. RF varies between 4.5 and 7 cycles per minute. Breathing at RF stimulates the cardiovascular system to oscillate at that frequency at a very high amplitude and greatly stimulates the baroreflex system. RFB is known to reduce depression and stress symptoms as well as various diseases related to malfunction of the autonomic nervous system, such as asthma and hypertension.
Study: NCT02229955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine ophthalmic solution
Description: 1 drop twice/day for 12 weeks to both eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine ophthalmic solution
Description: 1 drop twice/day for 12 weeks to both eyes
Study: NCT02908568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spring device
Description: Brisk dilatation of fhe mouth.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mandible stimulator
Description: Stimulation of fhe mouth.
Study: NCT00961259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid 35 mg Tablet
Description: 1 x 35 mg tablet administered after an overnight fast of at least 10 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid 35 mg Tablet
Description: 3 x 35 mg tablets administered after an overnight fast of at least 10 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid 105 mg Tablet
Description: 105 mg tablet administered after an overnight fast of at least 10 hours
Study: NCT01438632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: jet injection device
Description: Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: jet injection device
Description: Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.
Study: NCT01324024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
Study: NCT03112772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Puros® Allograft
Description: It is a type of bone grafting materials used for enhancing bone formation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CopiOs® Cancellous Particulate
Description: It is a type of bone grafting materials used for enhancing bone formation
Study: NCT02893215

Intervention type: OTHER
Intervention: Screening for silent AF with Zenicor thumb-ECG
Description: Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.

Intervention type: OTHER
Intervention: Screening for silent AF with Zenicor thumb-ECG
Description: Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.
Study: NCT02129179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon-Like Peptide 1
Study: NCT04377516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle training
Description: pelvic floor muscle training
Study: NCT02692833

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. This is an observational study of how patients' renal function responds to their surgery. The groups are defined by this response. There is no difference between clinical interventions between the two groups.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. This is an observational study of how patients' renal function responds to their surgery. The groups are defined by this response. There is no difference between clinical interventions between the two groups.
Study: NCT00935103

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Study: NCT01531959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Patients will be randomized to blinded to 20 mg of midodrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized to blinded placebo control
Study: NCT04744727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol-pethidine
Description: 100 ml containing 1000 mg paracetamol -50 mg pethidine HCL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol-pethidine
Description: 100 ml containing 1000 mg paracetamol -50 mg pethidine HCL
Study: NCT03616756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Authentic Connections
Description: Authentic Connections support groups for nurse leaders who are also mothers. Meetings occur once a week for one hour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protected time
Description: Participants have one hour per week protected time scheduled on their calendar to do with what they choose.
Study: NCT00120042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 600 mcg misoprostol swallowed after delivery of fetus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 10 units oxytocin administered intramuscularly after delivery fetus
Study: NCT01810978

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bifidobacterium lactis plus inulin
Description: 5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: same amount of maltodextrin per day will be given as placebo
Study: NCT05368597

Intervention type: PROCEDURE
Intervention: PCI in native vessel or in bypass graft
Description: Native vessel PCI,which choose native coronary artery as the target vessel, while the bypass graft PCI choose graft vessel as the target vessel.

Intervention type: PROCEDURE
Intervention: PCI in native vessel or in bypass graft
Description: Native vessel PCI,which choose native coronary artery as the target vessel, while the bypass graft PCI choose graft vessel as the target vessel.
Study: NCT02804165

Intervention type: GENETIC
Group type: OTHER
Intervention: Enterovirus vaccination
Description: Enterovirus vaccination in genetically predisposed subjects having a high risk to develop type 1 diabetes.
Study: NCT03905759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronedarone
Description: Dronedarone (200 mg twice daily starting from day before operation till 5 days after)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
Study: NCT04692246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based oral rinse
Description: Oral rinse enriched with plant-based essential oils.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral rinse
Description: Oral rinse with the exact characteristics in terms of colour and odour of the plant-based one, but without the essential oils aimed to test in this study
Study: NCT02252081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 500 to 1500 mg orally per day for 16 weeks if eGFR \> 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =\< 45 ml/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill(s) orally per day for 16 weeks
Study: NCT04273100

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PD-1 mAb combined with TACE and lenvatinib
Description: the combination of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE) and anti-angiogenic therapy (lenvatinib)